

**Guidance for the public
health management of
Escherichia coli O157
and other Shiga toxin-
producing (STEC)
infections.**

**Evidence-
Based
Guideline
(EBG).**

**Scottish Health
Protection Network
Scottish Guidance
No 3 (2018 edition).**

Document Amendment Log

Version	Date	Page Number	Amendment Summary

The Scottish Health Protection Network (SHPN) is a network of existing professional organisations and networks in the health protection community across Scotland. It aims to promote, sustain, and coordinate good practice. The SHPN supports a systematic approach to development, appraisal and adaptation of guidelines, seeking excellence in health protection practice.

Health Protection Network site: <http://www.hps.scot.nhs.uk/about/HPN.aspx>

Supported by Health Protection Scotland

Health Protection Scotland (HPS) is a non-profit, public sector organisation which is part of the Scottish National Health Service. It is dedicated to the protection of the public's health.

Citation for this document

Scottish Health Protection Network. Guidance for the public health management of *Escherichia coli* O157 and other Shiga toxin-producing (STEC) infections. Scottish Health Protection Network. Scottish Guidance 3 (2018 Edition). Health Protection Scotland, Glasgow, 2018.

Published by Health Protection Scotland

Meridian Court, 5 Cadogan Street, Glasgow, G2 6QE.

Health Protection Scotland is a division of NHS National Services Scotland.

First published October 2008

© Scottish Health Protection Network 2018

The Scottish Health Protection Network has made every effort to trace holders of copyright in original material and to seek permission for its use in this document and the associated quick reference guide. Should copyrighted material have been inadvertently used without appropriate attribution or permission, the copyright holders are asked to contact the Scottish Health Protection Network so that suitable acknowledgement can be made at the first opportunity.

The Scottish Health Protection Network consents to the photocopying of this document for the purpose of implementation in NHSScotland.

All other proposals for reproduction of large extracts should be addressed to:

Scottish Health Protection Network

Health Protection Scotland

Meridian Court, 5 Cadogan Street

Glasgow G2 7HF

Tel: +44 (0) 141 300 1100

Email: nss.hpsenquiries@nhs.net

Table of Contents

Feedback on the guidance	iv
Abbreviations	iv
1. Introduction	1
1.1 Changes in this edition	1
2. Case definitions	2
3. Background	4
3.1 The pathogen	4
3.2 Clinical features	4
3.2.1 Infectious period	5
3.2.2 Transmission	5
3.3 Sources	6
3.3.1 Food borne	6
3.3.2 Non-food borne	6
4. Epidemiology in Scotland	7
4.1 Incidence	7
4.2 Age	7
4.3 Seasonality	7
4.4 Morbidity/Mortality	8
4.5 Sporadic/outbreak	8
5. Microbiology	9
5.1 Local Laboratory Diagnosis	9
5.2 Reference Laboratory Diagnosis	10
5.2.1 Role of the Reference Laboratory	10
5.2.2 Detection of antibodies in serum samples	11
5.2.3 Interpretation of PCR positive stool sample results not confirmed by culture	11

5.2.4 Shiga toxin (stx) gene negative <i>E. coli</i> O157	11
5.2.5 Whole Genome Sequencing (WGS)	12
5.2.6 Microbiological clearance testing	12
5.2.7 Reference Laboratory Reporting	12
6. Public Health Action for STEC	13
6.1 Local planning	13
6.1.1 Surveillance	13
6.1.2 Identification	13
6.2 Risk assessment	14
6.3 Control measures	15
6.3.1 Exclusion and clearance	15
6.3.2 Compliance	17
6.3.3 Chronic shedding	17
6.4 Outbreak management	17
6.4.1 Special circumstances	18
6.4.2 Nurseries and other early years establishments	18
6.4.3 Open farms or petting zoos	18
7. Flowchart	20
8. Guidelines Review Group (Membership)	21
9. Guidelines Review Process	22
9.1 Acknowledgements	22
10. References	23

Feedback on the guidance

Comments on this guidance should be sent to the SHPN Guidance Group by emailing NSS.SHPN@nhs.net.

Abbreviations

APHA	Animal and Plant Health Agency – https://www.gov.uk/government/organisations/animal-and-plant-health-agency
DWQR	Drinking Water Quality Regulator – http://dwqr.scot/
EHD	Environmental Health Department
EHEC	Enterohaemorrhagic <i>E. coli</i>
EPEC	Enteropathogenic <i>E. coli</i>
FSS	Food Standards Scotland – http://www.foodstandards.gov.scot/
GBRU	Gastrointestinal Bacteria Reference Unit
HPS	Health Protection Scotland – http://www.hps.scot.nhs.uk/
HPT	Health Protection Team
HUS	Haemolytic Uraemic Syndrome
IMT	Incident Management Team
IQR	Interquartile range
MPHI	Scottish Government. Management of Public Health Incidents: Guidance on the Roles and Responsibilities of NHS led Incident Management Teams. Scottish Guidance No 12 (2017 edition). Scottish Health Protection Network. Available from: http://www.hps.scot.nhs.uk/guidelines/detail.aspx?id=1266
PAG	Problem Assessment Group
PCR	Polymerase Chain Reaction
SEPA	Scottish Environment Protection Agency - https://www.sepa.org.uk/
SERL	Scottish <i>E. coli</i> O157/STEC Reference Laboratory
SF	Sorbitol fermenting
STEC	Shiga toxin-producing <i>E. coli</i>
stx	Shiga toxin
TMA	Thrombotic microangiopathy
TTP	Thrombotic thrombocytopenic purpura
VTEC	Verocytotoxigenic <i>E. coli</i>
WGS	Whole Genome Sequencing

1. Introduction

Over a number of years, there has been a large amount of work to reduce the burden of disease from *E. coli* O157 through a host of interventions aimed at preventing, or minimising risk of, infection.

However, cases still occur, both sporadically and in outbreaks, and rapid response to these situations is necessary for protection of the public health. Additionally, there has been an increase in the number of non-O157 STEC, and increasing evidence of the disease burden of *E. coli* O157 Shiga-toxin negative organisms.

This guidance does not replace individual expert clinical judgement or local response arrangements, but is designed to support the development of those arrangements and assist in response to *E. coli* cases by health protection teams, environmental health departments and other stakeholders.

This document replaces the 2013 Guidance for Public Health Management of Infection with Verotoxigenic *Escherichia coli*. It is part of a suite of materials that has been produced in parallel, which also includes a clinical guideline and a template patient information leaflet.ⁱ In addition it should be used alongside the [Scottish STEC Enhanced Surveillance Form](#).

Whilst reference is made in this document to outbreak/incident response, infection control, and water treatment and supply, detailed discussion of these topics is out with the remit of this guidance and can be found elsewhere.

1.1 Changes in this edition

- Updates to the current epidemiology of *E. coli* in Scotland, including the increase in non-O157 STEC.
- An expanded and more detailed guide to local diagnostic and reference laboratory testing procedures and services.
- Removal of sections on clinical management – now covered by the clinical guideline.ⁱ
- Refresh of text on public health action, including new, simplified algorithm. Clarification on the need for public health action for all *E. coli* O157 (*stx* positive and negative) and *stx* positive *E. coli* of other types.

ⁱ A link to the clinical guidance and the patient information leaflet will be added when they are published.

2. Case definitions

The case definitions are provided to assist in ensuring a co-ordinated and consistent approach, but cannot be comprehensive of all situations; notably, when outbreaks occur, Incident Management Teams (IMT) should agree a more appropriate case definition for each circumstance.

Possible case:

A case where STEC is considered in the differential diagnosis but another diagnosis is as, or more likely and where there is no known epidemiological link.

Probable case:

A case with gastrointestinal symptoms and a known epidemiological link to a confirmed case.

OR

A case with significant clinical illness, such as acute bloody diarrhoea, and no epidemiological link.

OR

A case with Haemolytic Uraemic Syndrome (HUS).

Presumptive positives: A positive *E. coli* O157 slide agglutination result is obtained on morphologically typical colonies, pending full identification of the organism as *E. coli*.

Confirmed case:

A case which has been microbiologically confirmed:

Locally confirmed case: Isolation of *E. coli* O157 from a clinical specimen OR detection of *E. coli* O157 nucleic acid or Shiga toxin genes in a clinical specimen.

Reference laboratory confirmed case: Isolation of *E. coli* O157 or non- O157 Shiga toxin-producing *E. coli* from a clinical specimen OR detection of IgM antibodies to Shiga toxin-producing *E. coli* in serum.

Terms such as 'provisional' should be avoided.

Close Contacts

- All household contacts. This includes those who shared a kitchen or toilet facilities with the case during the infectious period. This may include extended family members,

childminders and their families, as well as sexual contacts. It also includes occasions where the case has stayed overnight away from home.

- Any individual the case has regularly prepared food for, during the infectious period, or on a single occasion if there are concerns about hygiene practices.
- If appropriate, anyone involved in nappy changing, assisted toileting, or personal care of the index case during the infectious period.

3. Background

3.1 The pathogen

Escherichia coli (*E. coli*) are gram negative, rod-shaped bacteria commonly found in the intestines of humans and animals making up part of the normal gut flora. Most are harmless; however, certain types of *E. coli* are harmful to humans.¹

The enterohaemorrhagic *E. coli* (EHEC) are now generally referred to as Shiga toxin-producing *E. coli* (STEC). They are capable of producing the toxins Shiga toxin 1 (stx1) and Shiga toxin 2 (stx2) (named due to their similarity to the toxin produced by *Shigella dysenteriae* type 1). STEC replaces the previous terminology 'verocytotoxin-producing *E. coli* (VTEC)'.¹

Shiga toxin can be produced by both O157 and non-O157 serotypes. All O157 types (stx +ve and -ve) and non-O157 STEC (i.e. stx +ve) infections require urgent Public Health action.

3.2 Clinical features

Symptoms of STEC infection range from asymptomatic infection, to mild non-bloody diarrhoea, through to bloody diarrhoea (around half of people infected will have bloody diarrhoea), abdominal pain and occasionally fever.

Some people may go on to develop very serious complications such as haemolytic uraemic syndrome (HUS),² and in a small number of cases infection may prove fatal.

Approximately, 10-15% of people infected with STEC go onto develop HUS.³

Children under 15 years old and older adults over the age of 65 years⁴ are more likely than other age groups to develop STEC-related HUS, particularly children under 5 years. In England between 2009 and 2012, three quarters of HUS cases occurred in children (0-14 years).⁵

For more information on the clinical aspects of STEC infection, see clinical guidelines.ⁱⁱ

Incubation period

The incubation period for diarrhoeal illness caused by STEC O157 infection is usually three to four days, with a range of one day to ten days, but has been occasionally recorded as long as 14 days.^{6,7,8,9} However, even longer incubation periods have also been noted.¹⁰ It can be difficult to distinguish co-primary cases with longer incubation periods from secondary cases with shorter ones.

ii A link to the clinical guidance and the patient information leaflet will be added when they are published.

3.2.1 Infectious period

Infectivity is generally seen to be greater whilst symptomatic.¹¹ However, as cases are infectious even if asymptomatic the possibility of being infectious before symptoms start cannot be ruled out¹² and cases remain infectious until they have 'cleared' the infection, i.e. until STEC can no longer be detected in the faeces.¹³⁻¹⁴

STEC can be 'shed' in faeces intermittently¹⁵ and shedding times vary, but are typically from 2-62 days with varying means/medians in different studies – 13,17 or 30 days.¹⁶⁻¹⁷ A small number of individuals have been reported to shed STEC for over six months,¹⁸ which is consistent with findings from Scotland (personal communication). There is some evidence to suggest that the shedding times for patients with HUS might be longer at 5-124 days with an average of 21 days¹⁹⁻²⁰

The shedding time of young children is of particular interest due to the necessity to exclude them from childcare facilities. A paper from Ireland analysed 10 years of data on the number of days children under the age of six years took to microbiologically clear STEC infection. The median clearance time for all the children was 39 days, interquartile range (IQR) 27-56 days, longest clearance time 283 days. At 70 days from onset of infection, 90% of children had cleared the infection. There is some evidence that asymptomatic children cleared STEC infection faster than symptomatic children. Symptomatic children older than 1 year of age cleared STEC infection faster (than symptomatic children under 1 year of age).²¹

3.2.2 Transmission

STEC are found in the intestines of farmed²²⁻²³ and wild ruminant animals,²⁴ mainly cattle,²⁵ sheep and goats including calves,²⁶ lambs²⁷ and kids. Other animals have been shown to be colonised with STEC, such as deer. Most animals carrying STEC will show no signs of illness.²⁸

The fact that STEC can be found in the intestines of these animals means that STEC can also be present in their faeces²⁹ and hence anywhere their faeces may come into contact with, such as:

- The animals themselves, even if they look clean and well;
- Land where they have been grazing;
- Fences, gates and surfaces around the farm or grazing land;
- Petting farms where these animals are kept;
- Anywhere where the animal faeces may have spread through contact with vehicles, footwear, clothing worn on farms, pushchair wheels etc;
- Rivers, streams, lochs and inadequately treated water supplies where the faeces may have washed into from the land;
- Raw meats and undercooked animal products and unpasteurised milk and other dairy products made from unpasteurised milk;

- Other food stuffs which may have become contaminated by animal faeces or contaminated irrigation water, such as raw vegetables and salad.

Secondary transmission also occurs within households and other close settings such as nurseries-. The highest proportion of secondary cases are as a result of child to child transmission, and secondary cases are more common when the age of cases is <6 years-.

3.3 Sources

3.3.1 Food borne

STEC was initially associated with minced beef products, for example, beef burgers.^{34,35,38} Minced meat products are higher risk due to the fact that any bacteria present on the surface of the meat will have been mixed throughout the product after mincing.³⁷

However, STEC has also been associated with a range of other foods.³⁸⁻³⁹

Other meat products that are documented to have caused STEC outbreaks include venison,⁴⁰ pork,⁴¹⁻⁴² mutton⁴³ and cooked meats.⁴⁴

Unpasteurised milk and milk products, such as cheese, are another source of STEC⁴⁵⁻⁴⁶ Pasteurised products have also been traced as the probable source of outbreaks where pasteurisation failure or post-pasteurisation contamination has occurred.⁴⁷⁻⁴⁸

Food products not immediately identified as being linked to animals such as lettuce,⁴⁹⁻⁵⁰ including bagged lettuce⁵¹⁻⁵² sprouted seeds,⁵³ watercress,⁵⁴ leeks,⁵⁵ potatoes,⁵⁶ berries⁵⁷ and raw cookie dough⁵⁸ have also been identified as the source of outbreaks. Modes of contamination identified include direct contamination with animal faeces, manures and slurries,⁵⁹ irrigation with contaminated water⁶⁰ and cross-contamination with animal products in food preparation areas.^{61,62,63}

Infected food handlers have also been traced as the probable source of STEC outbreaks.⁶⁴

3.3.2 Non-food borne

The fact that STEC is found in the intestines of some animals, and hence anywhere their faeces may come into contact with, means that STEC is likely to be present on farms, petting farms and grazing land; and may also be found in untreated water from lochs, rivers and streams, or from private water supplies that have not been adequately treated.

Outbreaks have occurred from non-food borne sources involving direct or indirect contact with animals including farms,⁶⁵⁻⁶⁶ petting farms / zoos,^{67,68,69} country fairs,⁷⁰ camps, music festivals,⁷¹ recreational water activities⁷²⁻⁷³ and private water supplies.⁷⁴

4. Epidemiology in Scotland

4.1 Incidence

Health Protection Scotland (HPS) has an established enhanced surveillance system, in close collaboration with the Scottish *E. coli* O157/STEC Reference Laboratory (SERL).

Reports of STEC O157 infection in Scotland increased markedly in the mid 1990s and rates remain high when compared with other UK and European countries.⁷⁵

The number of STEC O157 infections in Scotland has remained reasonably steady over the last 10 years, with an average of 220 per year.

However, the number of non-O157 STEC infections has steadily increased, partially driven by a change in referral pattern for diagnostic testing. Over the past five years, the non-O157 infections reported have accounted for an average of 20% of STEC cases.

Phage type (PT) 21/28 and PT 8 are the most commonly occurring in Scotland accounting for an average of 39% and 23% respectively of STEC O157 cases over the past five years.

Geographical distribution of incidence varies in Health Board areas around Scotland. However, interpreting the rates in smaller Health Board areas is difficult as the small numbers disproportionately affect the incident rates, and all Boards' rates can be affected by large outbreaks.

4.2 Age

For cases occurring between 2012 and 2016, the age of cases ranged from under 1 to over 90 years with a mean age of 31.9 years, median 28 years. Children under 16 accounted for 33% of infections with the highest rate of infection being in the 0-4 year old age group.

4.3 Seasonality

Case numbers tend to be higher in the summer months. Approximately 60% of the cases in Scotland (2012-2016) were reported between weeks 21 and 40. This equates to mid May to the end of September. Numerous reasons for this fluctuation have been suggested such as travel, environmental factors, cattle shedding patterns, differences in food handling and recreational activities in the summer months and housefly populations.⁷⁶

Travel

Of the STEC cases in 2016, 15% were reported to have travelled outside the UK in the 14 days prior to the onset of symptoms.

4.4 Morbidity/Mortality

Overall in 2015 and 2016, 36% of STEC cases were admitted to hospital for at least one night during their illness. In terms of symptoms, 5% of STEC cases were asymptomatic, 21% had diarrhoea without blood and 71% had bloody diarrhoea.

Approximately, 9% cases of STEC in Scotland developed Haemolytic Uraemic Syndrome between 1999 and 2008.⁷⁷ Similar proportions have been observed in more recent years.


The mortality rate in children with HUS is reported in the literature to be between 3% and 5% with most deaths being due to severe extrarenal complications including central nervous system involvement.⁷⁸

4.5 Sporadic/outbreak

The majority of cases in Scotland are sporadic. However, a number of general outbreaks (defined as affecting more than one household) do occur. In the ten years between 2008 and 2017, there was an average of six STEC general outbreaks a year.

In the ten years 2008-2017 (Figure 1), 18 STEC general outbreaks were reported in Scotland where the main mode of transmission was foodborne or multiple modes, including a foodborne component. Suspected foods were identified in 10 of these outbreaks; meat/meat products in five, salad leaves in two, vegetables in one, and other foods in two.

Figure 1: outbreaks of STEC 2008-2017 in Scotland



5. Microbiology

Definitive diagnosis of STEC infection in diagnostic (local) laboratories is obtained by culture of STEC from stool samples or detection of antibodies in a serum sample.

5.1 Local Laboratory Diagnosis

Scottish diagnostic laboratories routinely test all submitted stool specimens for the presence of non-sorbitol-fermenting *E. coli* O157 but not for non-O157 STEC or sorbitol-fermenting *E. coli* O157.

Clinical history of bloody diarrhoea, HUS or other relevant presenting feature should be noted on the laboratory request form.

Culture confirmation of *E. coli* O157 at the diagnostic laboratory will take 24-48 hours from receipt of the sample (local confirmation).

In general, this is obtained by the following steps:

1. Examination of colonial morphology on selective media (day 1);
2. Performing a slide agglutination test on single colonies (this is usually an *E. coli* O157 kit- based test) (day 1);
3. Confirmation of the identity of slide agglutination positive colonies as *E. coli* (usually day 2).

When all 3 steps have been carried out, the isolation of *E. coli* O157 from the sample is 'locally confirmed'.

Most diagnostic laboratories employ kit- based slide agglutination tests which have a very low rate of false positive results. The diagnostic laboratories will therefore usually inform the clinician and the local Health Protection Team immediately if a positive *E. coli* O157 slide agglutination result is obtained on morphologically typical colonies, pending full identification of the organism as *E. coli*. These are termed "presumptive positives".

Urgent notification to the Health Board of possible, presumptive or confirmed STEC infection is required under the Public Health etc. (Scotland) Act 2008.⁷⁹

Written or electronic notification of the result is issued within 3 days.

Isolates should then be sent to the Reference Laboratory for final confirmation of identity and typing. The appropriate clinical and public health management of potential STEC infection should not be delayed whilst awaiting Reference Laboratory results.

Microbiological confirmation of infection with non- O157 STEC, or atypical *E. coli* O157 strains is more difficult.

If enteric pathogen molecular diagnostic methods are in use at the local laboratory, it is possible to obtain a rapid local positive PCR result, which will be immediately reported to

the clinician and the local Health Protection Team. It is important to assess the significance of a positive PCR result, taking account of the clinical and public health information on the case. Appropriate clinical and public health management should not be delayed pending culture confirmation, which may take several days. In some cases, culture confirmation is not possible.

More detailed guidance on the interpretation of PCR assays for STEC is available on the Health Protection Scotland Website: <http://www.hps.scot.nhs.uk/guidelines/detail.aspx?id=1561>.

5.2 Reference Laboratory Diagnosis

The Scottish *E. coli* O157/STEC Reference Laboratory accepts stool samples for molecular testing from cases that meet the following criteria:

- Cases of suspected HUS or cases of bloody diarrhoea in whom conventional laboratory testing has failed to yield a pathogen;
- All symptomatic contacts of non-sorbitol-fermenting *E. coli* O157, sorbitol-fermenting *E. coli* O157 and non- O157 STEC in whom conventional laboratory testing has failed to yield a pathogen;
- Any outbreak- associated case in whom conventional laboratory testing has failed to identify a pathogen.

The Reference Laboratory will carry out molecular testing by PCR, followed by culture if the stool sample is PCR positive. Positive PCR results will be telephoned, immediately, to the referring diagnostic laboratory.

5.2.1 Role of the Reference Laboratory

For Scotland, the Reference Laboratory is the Scottish *E. coli* O157/STEC Reference Laboratory (SERL).

A variety of services is provided, including the following:

- Confirmation of identity and relevant typing e.g serotyping, phage typing, molecular typing including whole genome sequencing
- Detection of virulence genes, and other genes as appropriate
- Antimicrobial resistance data for national surveillance (not routinely reported to clinicians or Health Protection Teams)
- Provision of advice to clinicians, public health and epidemiology colleagues at NHS Board level and national level
- Provision of advice to Local Authority scientific services, and other bodies in relation to food, water and environmental isolates as required

In addition to human isolates, the SERL accepts isolates of STEC from food, water or environmental sources by arrangement by telephone. Isolates submitted in the course of

outbreak investigations are routinely processed by SERL and will be prioritized along with human isolates.

The SERL User Manual can be accessed at the following site: <http://www.edinburghlabmed.co.uk/Specialities/reflab/ecoli/Pages/default.aspx>.

5.2.2 Detection of antibodies in serum samples

Diagnostic laboratories should submit a sample of serum (not clotted blood) if stool samples are negative or no stool sample is available in cases where HUS is a likely diagnosis. This is a referred test (GBRU, Colindale) and the turnaround time is 10 days if samples are referred via the SERL. Serum samples may also be sent directly from the diagnostic laboratory to GBRU, Colindale.

5.2.3 Interpretation of PCR positive stool sample results not confirmed by culture

Reference Laboratory data has shown that approximately 16% of stool samples which are positive for Shiga toxin genes at SERL fail to yield a STEC organism on culture.

Interpretation of these results should be based on the clinical presentation and the detection of other enteric pathogens.

5.2.4 Shiga toxin (stx) gene negative *E. coli* O157

E. coli O157 strains testing negative for stx genes are isolated as a result of referral of faecal samples from cases of bloody diarrhoea which are locally culture negative to the Reference Laboratory. These isolates are frequently sorbitol- fermenting and are more difficult to detect by current diagnostic laboratory methodologies. In Scotland in 2015, 6.5% of *E. coli* O157 strains tested negative for stx genes ([HPS Weekly Report 18 October 2016](#)).

A proportion of these strains are descendents of enterohaemorrhagic *E. coli* O157 that have lost the stx gene during infection but have caused significant disease, including HUS.^{80,81,82}

Therefore the initial assumption should be that Public Health actions such as screening and exclusion should be carried out. Advice on the potential pathogenicity of individual strains may be obtained from the Reference Laboratory, but clinical and epidemiological features of the case should also be taken into account. A risk assessment may be required if a case continues to excrete a stx gene negative *E. coli* O157, taking account of the clinical presentation and circumstances of the case.

Non- bloody diarrhoea may be caused by *E. coli* strains (non- O157 serotype) designated Enteropathogenic *E. coli* (EPEC). These are also stx gene negative. Diagnostic laboratories do not investigate faecal samples for these organisms as illness is usually mild and self-limiting.

5.2.5 Whole Genome Sequencing (WGS)

Additional information provided by whole genome sequencing of STEC organisms may inform risk assessment for Public Health purposes – e. g. possession of *eae*, *aggR* and *aaiC* genes –, which are involved in adherence of the organisms to the gut. Isolates of *E. coli* O157 are *eae* positive but possession of *eae* genes in non- O157 STEC is variable.⁸³ However, possession of *eae* gene is usually, but not always, an additional requirement for the organism to cause severe disease.⁸⁴

Genetic elements involved in the pathogenicity of STEC are mobile and new pathogenic strains emerge in the human and cattle population and in foodstuffs e.g. the *eae* gene negative, *stx* and *aggR* positive *E. coli* O104 which caused a large outbreak of HUS in Germany.⁸⁵

WGS also provides information on *stx* subtype and some subtypes e.g. *stx* 2a and *stx* 2d are associated with more severe disease.⁸⁶⁻⁹²

5.2.6 Microbiological clearance testing

Microbiological clearance for non-sorbitol-fermenting *E. coli* O157

Microbiological clearance: for non- sorbitol- fermenting (NSF) *E. coli* O157 with or without *stx* genes is confirmed by conventional laboratory testing (culture) at the local diagnostic laboratory; this is irrespective of whether or not the local diagnostic laboratory initially cultured the STEC.

Microbiological clearance for sorbitol-fermenting *E. coli* O157 and non-O157 STEC

Microbiological clearance for sorbitol-fermenting *E. coli* O157 is confirmed at SERL by PCR for detection of *stx1*, *stx2*, and *rfbO157* genes.

Microbiological clearance for non- O157 STEC is confirmed at SERL by PCR for detection of *stx1* and *stx2* genes.

Samples are reported by SERL as positive or negative based on interpretation of the PCR result.

Diagnostic laboratories employing PCR methodology for STEC detection may be able to locally confirm microbiological clearance of SF and non- O157 STEC.

5.2.7 Reference Laboratory Reporting

Reports are issued electronically. Important or urgent results are telephoned to the referring diagnostic laboratory – e.g. new positive results on faecal samples. See the SERL User Manual - <http://www.edinburghlabmed.co.uk/Specialities/reflab/ecoli/Pages/default.aspx> - for further information.

6. Public Health Action for STEC

STEC infection can cause significant and potentially severe disease, hence the need for rapid public health intervention. The key to public health action for STEC is detailed risk assessment to ascertain a) the likely source of infection b) the likelihood of further primary or secondary cases, and c) to inform the subsequent implementation of measures to remove or mitigate those risks.

Public health response to an STEC case must start on the day of notification, and as a minimum standard, the risk assessment should be completed and subsequent public health actions initiated within 24 hours of notification.

6.1 Local planning

Whilst this guidance provides general information on risk assessment, case management and outbreak control, and can be used as the basis for local planning, it does not replace the need for such planning. The implementation of this guidance at local level will be influenced by factors including, but not limited to, geography and demography, available resources, and accessibility of other services.

To assist effective working arrangements, a specific standard operating procedure, service level agreement or similar – which meet or exceed the minimum standard above, should be agreed between public health teams and local environmental health departments. Arrangements with other agencies should be detailed in local or national plans. Other agencies who may be involved dependent on the scenario include: Health Protection Scotland (HPS); the Animal and Plant Health Agency (APHA), Scottish Environment Protection Agency (SEPA); Scottish Water; Drinking Water Quality Regulator (DWQR), and Food Standards Scotland (FSS). Implementation of this guidance, and post-action reviews (lessons learned) should form part of the work plan of the Board health protection liaison groups.

6.1.1 Surveillance

Since 1999, *E. coli* O157 and other STEC have been subject to an enhanced surveillance system in Scotland. The enhanced surveillance form was fully revised and updated in 2016, and is approved for use as part of the data sharing arrangements between HPS and territorial Boards.

6.1.2 Identification

Cases will usually be notified by either local microbiology laboratories, or SERL. Cases may also be reported by clinical staff where there is suspicion of STEC, for example cases with acute bloody diarrhoea, or in cases of haemolytic uraemic syndrome (HUS).

Further guidance on diagnosis is contained in the microbiology section and in the clinical guideline.ⁱⁱⁱ

ⁱⁱⁱ A link to the clinical guidance and the patient information leaflet will be added when they are published.

6.2 Risk assessment

The investigation should begin with the collection of the information necessary to make the risk assessment. The HPS enhanced surveillance form must be used to ensure complete collection of this information about every case. The information may come from the case, contacts, or other informants.

Key areas to consider during the risk assessment are based on the known epidemiology of the disease, including source and transmission factors, which are described in the first section of this guidance. These include:

- Case details, including age, occupation, and underlying medical conditions.
- Details of workplace (including health, care or food handling responsibilities) or educational establishment, including nurseries or other care settings.
- Food history, especially any history of eating out, takeaways, handling of produce contaminated with soil, and handling or consumption of raw, unpasteurised, unusual, or imported foods.
- Contact with animals. Careful questioning, including specific questions on household pets, is required as individuals may have differing definitions of domestic v wild animals.
- Use of water. There is a higher risk from private water supplies, and contact with surface water such as lochs or streams. Risk from public water supply is very low unless there has been a failure of treatment or significant works on the water network.
- Travel history should include not just foreign travel, but any overnight stays elsewhere in the United Kingdom, as STEC is endemic to the UK.
- Consideration of other activities, day trips or hobbies, such as hillwalking or rural sports, which may bring the individual into close contact with animal faeces.

The risk assessment should also include gathering of details of all close contacts, including sufficient information to assess if they fall into risk categories. [Close contacts](#) (Section 2) can be defined as follows:

- All household contacts, including those made through overnight stays. This includes those who shared a kitchen or toilet facilities with the case, during the infectious period. This may include extended family members, childminders and their families, as well as sexual contacts.
- Any individual the case has regularly prepared food for, during the infectious period, or on a single occasion if there are concerns about hygiene practices.
- If relevant, anyone involved in nappy changing, assisted toileting, or personal care of the index case during infectious period.

Contacts who are symptomatic should be treated as a probable case, with appropriate clinical and public health management.

Further investigations to identify or confirm the source may be necessary. These may include case finding, additional microbiology testing, environmental inspection, and food or water testing. The Health Protection Team (HPT) and Environmental Health Department

(EHD), with HPS and other agencies as necessary, should discuss and agree what, if any, further investigation is required for single cases. It is expected that in clusters/outbreaks this decision would be taken by the IMT. In the event that a case(s) used private water supplies in the incubation period, it would be expected that sampling of the supply would occur, and alternative temporary water supplies utilised, pending results.

6.3 Control measures

Working with Environmental Health Departments and other agencies as appropriate, the local public health team should initiate actions to mitigate the risk from any identified source, and to reduce the risk of future transmission. These should be proportionate to the risk and may invoke use of the precautionary principle.

Cases and contacts should be provided with information and advice on reducing the risk of further spread. Advice should be given both verbally and in writing. Local public health teams should give consideration to use of standardised patient information leaflets.^{iv}

As with all GI pathogens, the key intervention is good infection-control practice, in particular hand hygiene. The importance of washing hands with liquid soap and running warm water, as well as drying thoroughly with a separate towel, every time after using the toilet and before food preparation should be stressed.

Hand washing should also be performed after any other activity where faecal contamination is a possibility, for example the handling of soiled linen, contact with animals, and before and after assisting younger children with toileting, including nappy changing.

Symptomatic individuals should not, if possible, prepare food for others, or share towels, and should be discouraged from swimming until 48 hours after symptoms cease. They should also refrain from sexual contact during this time.

Environmental cleaning should be reinforced, with special attention paid to toilets and surrounding areas, food preparation areas, and other hard surfaces such as sinks taps and door handles. Cleaning in nondomestic settings such as healthcare, daycare, or food businesses is detailed elsewhere.⁹³⁻⁹⁶ In particular food businesses should discuss their needs with the local environmental health department.

6.3.1 Exclusion and clearance

All cases should be advised to refrain from attending work or educational establishment (including nurseries, schools and universities or colleges) until 48 hours after diarrhoea and/or vomiting have resolved. This exclusion should also extend to other group settings such as playgroups and sports clubs.

Cases and close contacts who fall into one or more of the risk groups A to D (Table 1) should be, under the Public Health Act, formally excluded or restricted, in writing, from work or school until microbiological clearance has been achieved ([see flowchart, page 20](#)).

^{iv} A link to the patient information leaflet will be added when they are published.

Table 1: Risk Groups (cases and close contacts) adapted from Food Standards Agency Scotland (2006, Review) Guidance on the investigation and control of outbreaks of foodborne disease in Scotland (Cairns Smith Report). Available at: <http://www.hps.scot.nhs.uk/giz/resourcedetail.aspx?id=187>.

RISK GROUP	DEFINITION
Group A	Any person of doubtful hygiene or with unsatisfactory toilet, hand-washing or hand drying facilities at home, work or school.
Group B	Children, who attend pre-school groups or nursery
Group C	People whose work involves preparing or serving unwrapped foods not subject to further heating.
Group D	Clinical and social care staff who have direct contact with highly susceptible patients or persons in whom a gastrointestinal infection would have particularly serious consequences

Children attending preschool/nursery should be excluded under risk group B. In general, children under 5, not attending nursery/preschool fall under risk group A. Older children (5 to 10 years) may also fall into this risk group if there are concerns about hygiene practices, and an individualised risk assessment should be performed.⁹⁷ Group D may also include those working in early years care and education.

The Scottish CPHM Good Practice Statement⁹⁸ remains a reasonable standard for microbiological clearance, when compared to the global literature.⁹⁹⁻¹⁰² The risk group categories included in the table are currently under review by the SHPN as part of the Cairns Smith guidance review, and may be updated during the life of this document.

Microbiological clearance consists of two consecutive negative samples taken at least 24 hours apart. To ensure this gap, it may be appropriate to ask cases to take samples on 'alternate days'. Samples should be submitted as soon as possible after being taken, and to minimise potential sample errors, on different days. Samples should be also labelled with the time they were taken, as *per* the local laboratory protocol. The first clearance sample for the case should be taken no earlier than 48 hours after symptoms resolved.

Public health teams should decide on the timing of clearance samples in contacts in risk groups on an individual basis. Theoretically if clearance samples are taken from the close contact whilst the index case is still infectious, later cross infection may be missed. However the use of good personal hygiene and environmental cleaning would make transmission between competent adults very unlikely. The cross infection scenario is less likely with risk groups C and D as the nature of their work means they should have greater understanding of, and compliance to necessary hygiene measures, and as such clearance sampling could potentially begin at the same time as the case. For other contacts consideration should be given to delaying the start of clearance sampling, especially if either case or contact is in risk groups A or B.

The frequency of sampling should be discussed with the case. Sampling should not be too frequent, as multiple samples may result in difficult to interpret results, and are not an efficient use of lab resource.

Although exclusion will be the appropriate control measure for many cases, it should not be considered as the default option, and the least restrictive intervention necessary to protect

public health should be used. Consideration should always be given in the risk assessment to the use of restriction orders, for example limiting the types or locations of duties. Although still requiring some change to day-to-day activities, restriction orders are ultimately less disruptive to the individual and employer/school.

When using exclusion or restriction orders it is vital to follow the guidance published by the Scottish Government including ensuring the individual is aware of their rights to claim for loss of income.¹⁰³

Exclusion and restriction orders must be reviewed at least every 3 weeks.¹⁰⁴ Any decision on exclusion/restriction, and the risk assessment it is based on should be clearly documented.

6.3.2 Compliance

Control measures are only effective if there is a high level of compliance with strictly followed procedures. It is therefore important to ensure that control measures are understood and acceptable to those being asked to undertake them.¹⁰⁵

Teams responding to cases and outbreaks should consider audit of compliance with control measures as a means of both measuring performance, and informing future actions.

6.3.3 Chronic shedding

Individuals, especially young children, can continue to shed *E. coli* O157 / STEC in the stool for some time after the symptomatic infection has passed (see [Clinical features](#)). It is important that cases and/or parents are aware that clearance can be a lengthy process.

In some individuals, shedding can continue for a significantly longer time than the expected range. In these cases, it is appropriate to review the risk assessment, including any restrictions that have been placed on the individual. The public health benefit of any continued exclusion needs to be balanced against the potential harm from prolonged periods away from work or educational settings. Further risk assessment and consideration of alternative control measures (such as supervised hand washing) if necessary should occur for these cases.¹⁰⁶⁻¹⁰⁸ The timing of such a review will depend on the individual circumstances of the case, but six to eight weeks after notification is likely to be reasonable. In chronic shedding, reduction in the frequency of sampling should be considered. Where shedding continues for many months, consideration should be given to referral to the local infectious diseases team.

6.4 Outbreak management

Outbreaks should be managed in accordance with the HPS / Scottish Government Framework on [Management of Public Health Incidents](#) and the local outbreak control plan and other situation-specific national guidance.

Given the low infectious dose¹⁰⁹ and potential severity of STEC infection, a low threshold for action is appropriate. This includes the setting up of a problem assessment group (PAG) or an IMT. The initial PAG (if necessary) or IMT should be held on the same day as the outbreak

is detected or as soon as is practicable after. The first IMT meeting should specifically assess the ongoing risk to the public, consider what control measures are available, decide which activities should be prohibited or improved, and should identify who is responsible for completing each action.¹¹⁰

All outbreaks should be discussed with HPS and SERL. The Scottish Government Health Department should be informed, as in the Management of Public Health Incidents Guidance (2017).¹¹¹

6.4.1 Special circumstances

Whilst outbreaks of STEC should be managed to the same principles as any other outbreak investigation, there are certain circumstances where special considerations should be given. In these circumstances consideration should be given to widening the membership of the IMT to include other relevant stakeholders.

Outbreak control is more difficult in closed and semi-closed communities such as prisons, care homes, and other residential premises (including boarding schools) because of both the increased risk of spread, and potential barriers to implementation of control measures. Outdoor/rural events, such as organised camping/expeditions or charity and commercial events, require detailed risk assessment, and are beyond the scope of this guidance. Public health teams should follow any relevant plans and consider the need for early discussion and access to additional expertise and advice.

6.4.2 Nurseries and other early years establishments

All children attending these facilities will fall into risk group B, and many of the staff will carry out nappy changing or assisted toileting. Consideration should be given to how the infection was introduced and has spread around the setting. This should include assessment of the size, scope, layout, and operating procedures of the facility.

Aggressive control measures have been shown to stop school outbreaks.¹¹²⁻¹¹³ Control measures should include exclusion and testing of all symptomatic children and staff, reinforcement of rigorous hand hygiene measures, written information for parents and staff and enhanced environmental cleaning as detailed in the relevant HPS guidance.¹¹⁴

In certain circumstances the IMT may wish to consider screening asymptomatic individuals, or complete closure of the facility.¹¹⁵⁻¹¹⁷ If there are significant numbers of children excluded awaiting clearance who are now asymptomatic, it may be appropriate to consider cohorting if that is feasible given the design of the facility.¹¹⁸

These considerations can also be relevant in some adult day care settings.

6.4.3 Open farms or petting zoos

Attractions that bring about closer interactions with humans and farm or other animals have been associated with significant STEC outbreaks previously. In these settings there may be multiple zoonotic transmissions at the same time. As they are popular tourist attractions,

cases and contacts may be highly geographically dispersed making outbreak detection more difficult, and subsequently require an increased effort in case finding.


Urgent action to limit the possible further transmission including stopping all public access to the animals, and taking action to reduce possible contact between the public and animal faeces should be taken. Consideration should be given to closing the whole facility. HPT/EHD joint visits may be considered.¹¹⁹

The industry code of practice 'Preventing or controlling ill health from animal contact at visitor attractions or open farms,¹²⁰⁻¹²¹ which replaces HSE AIS 23,¹²² provides standards¹²³ that open farms and similar attractions should follow to minimise risks to visitors.¹²⁴⁻¹²⁵ Best practice guidance on planning events with animal-human interactions is also available.¹²⁶ In particular, keeping younger children out of animal pens/direct contact will help reduce risk.¹²⁷⁻

¹²⁸

7. Flowchart

Exclusion / Restriction Criteria for Cases and Contacts



8. Guidelines Review Group (Membership)

Names	Organisation / Role
Kennedy, Iain	CPHM, NHS Greater Glasgow and Clyde. Guideline Review Group (GRG) Chair
Bartram, Sara	Nurse Consultant (Health Protection), NHS Dumfries and Galloway
Browning, Lynda	Epidemiologist, Health Protection Scotland (HPS)
Byrne, Lisa	Public Health Lead, Public Health England (PHE)
Coia, John	Consultant Microbiologist, NHS Greater Glasgow and Clyde
Couper, Sarah	Consultant, Health Protection Scotland (HPS)
Jim Dixon	The Society of Chief Officers of Environmental Health in Scotland (SoCOEHS)
Dundas, Stephanie	Infectious Diseases Consultant, NHS Lanarkshire
Hanson Mary	Consultant Microbiologist, NHS Lothian. Director of SERL
Hawkins, Gill	Consultant, Health Protection Scotland (HPS). (GDG member until March 2017)
Lawrie, Brian	Environmental Health Team Leader, South Ayrshire Council
Mannes, Trish	Deputy Director for HP, Public Health England (PHE)
McAuley, Stephanie	Administrative Support Officer, Health Protection Scotland (HPS)
McGuire, Lesley	Project Manager, Health Protection Scotland (HPS)
Oshin, Femi	CPHM, NHS Lanarkshire
Riley, Andrew	Senior Medical Officer, Scottish Government
Sánchez-Vivar, Alex	Epidemiologist, Healthcare Scientist, Health Protection Scotland (HPS). Process support and expert assistance
Sandilands Helen	Scottish Government, Health & Social Care Directorate
Wellington, Louise	NHS Lothian

9. Guidelines Review Process

This guidance was developed using a standard methodology based on a systematic review of the evidence, in line with protocols supported by the Scottish Health Protection Network (SHPN). The evidence review and the appraisal process applied to the development of this guidelines, complies with the SHPN requirements for the production of evidence-based guidelines (EBG) type A. Further details can be found at: <https://hpsmicrosites.scot.nhs.uk/scottish-health-protection-network.aspx>

Keeping up to date

This guideline was published in 2018 and will be considered for review in three years. The review history, and any updates to the guideline in the interim period, will be noted in the review report.

9.1 Acknowledgements

We wish to express appreciation to all whose efforts made this guidance possible. In particular, to the members of the Guidance Development Group and their constituencies, PHI Digital Support at HPS, stakeholders and external reviewers, who contributed and reviewed the content of this guidance.

10. References

1. Pennington, T. H. (2014). *E. coli* O157 outbreaks in the United Kingdom: past, present, and future. *Infection and Drug Resistance*, 7, 211–222. <http://doi.org/10.2147/IDR.S49081>.
2. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing *Escherichia coli* and haemolytic uraemic syndrome. *Lancet* 2005; 365(9464):1073-86.
3. Pennington, TH (2010). *Escherichia coli* O157. *The Lancet* 2010; 376(9750): 1428-1435.
4. Dundas S, Todd WT, Stewart AI, Murdoch PS, Chaudhuri AK, Hutchinson SJ. The central Scotland *Escherichia coli* O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. *Clin Infect Dis* 2001; 33(7):923-31.
5. Byrne L, Jenkins C, Launders N, Elson R, ADAK GK. (2015). The epidemiology, microbiology and clinical impact of shiga toxin-producing *Escherichia coli* in England, 2009-2012. *Epidemiology and Infection*, 143(16), 3475-3487. doi:<http://dx.doi.org/10.1017/S0950268815000746>.
6. Brandt JR, Fouser LS, Watkins SL, Zelikovic I, Tarr PI, Nazar-Stewart V, et al. *Escherichia coli* O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. *J Pediatr*. 1994;125(4):519-26.
7. Keene WE, McAnulty JM, Hoesly FC, Williams LP, Jr., Hedberg K, Oxman GL, et al. A swimming-associated outbreak of hemorrhagic colitis caused by *Escherichia coli* O157:H7 and *Shigella sonnei*. *N Engl J Med*. 1994;331(9):579-84.
8. Public Health England (PHE) Surrey Independent Investigation Committee (2010) Review of the major outbreak of *E. coli* O157 in Surrey, 2009 - Report of the Independent Investigation Committee June 2010. Available from: <https://www.gov.uk/government/publications/escherichia-coli-e-coli-o157-report-and-recommendations-from-2009-godstone-incident>.
9. European Centre for Disease Prevention and Control. Systematic review on the incubation and infectiousness/shedding period of communicable diseases in children. Stockholm: ECDC; 2016.
10. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin--producing *Escherichia coli* infections. *Clin Microbiol Rev* 1998;11:450--79.
11. Thorpe CM (2004) Shiga Toxin—Producing *Escherichia coli* Infection, *Clinical Infectious Diseases*, Volume 38, Issue 9, 1 May 2004, Pages 1298–1303, <https://doi.org/10.1086/383473>.
12. Harries M, Dreesman J, Rettenbacher-Riefler S, Mertens E (2016) 'Faecal carriage of extended-spectrum -lactamase-producing Enterobacteriaceae and Shiga toxin-producing *Escherichia coli* in asymptomatic nursery children in Lower Saxony (Germany), 2014', *Epidemiology and Infection*, , pp. 1–9. doi: 10.1017/S0950268816001837.
13. MacDonald E, Dalane PK, Aavitsland P, Brandal LT, Wester LA, Vold L. Implications of screening and childcare exclusion policies for children with Shiga-toxin producing *Escherichia coli* infections: lessons learned from an outbreak in a daycare centre, Norway, 2012. *BMC Infectious Diseases* 2014; 14: 673.

14. Miliwebsky E., Deza N., Chinen I., Martinez Espinosa E., Gomez D., Pedroni E., Caprile L., Bashckier A., Manfredi E., Leotta G., Rivas M. Prolonged fecal shedding of Shiga toxin-producing *Escherichia coli* among children attending day-care centers in Argentina. *Revista Argentina de Microbiología*. 2007; 39 (2): 90-92.
15. European Centre for Infection Control and Prevention (ECDC) Systematic review on the incubation and infectiousness/shedding period of communicable diseases in children. Stockholm: ECDC; 2016. Available at: <https://ecdc.europa.eu/en/publications-data/systematic-review-incubation-and-infectiousnessshedding-period-communicable>.
16. Shah S, Hoffman R, Shillam P, Wilson B. Prolonged fecal shedding of *Escherichia coli* O157:H7 during an outbreak at day care center. *Clin Infect Dis*. 1996;23:835-6.
17. Keene WE, McAnulty JM, Hoesly FC, Williams LP, Jr., Hedberg K, Oxman GL, et al. A swimming-associated outbreak of hemorrhagic colitis caused by *Escherichia coli* O157:H7 and *Shigella sonnei*. *N Engl J Med*. 1994;331(9):579-84.
18. Brandt JR, Fouser LS, Watkins SL, Zelikovic I, Tarr PI, Nazar-Stewart V, et al. *Escherichia coli* O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. *J Pediatr*. 1994;125(4):519-26.
19. Karch H, Russmann H, Schmidt H, Schwarzkopf A, Heesemann J. Long-term shedding and clonal turnover of enterohemorrhagic *Escherichia coli* O157 in diarrheal diseases. *J Clin Microbiol*. 1995;33(6):1602-5.
20. Collins A, Fallon U, Cosgrove M, Meagher G, Ni Shuilleabhan C (2017). A 10-year analysis of VTEC microbiological clearance times, in the under-six population of the Midlands, Ireland. *Epidemiology and Infection*, 145(8), 1577-1583. doi:10.1017/S0950268817000425.
21. Gyles CL. Shiga toxin-producing *Escherichia coli*: an overview. *J Anim Sci* 2007;85:E45–E62.
22. La Ragione RM, Best A, Woodward MJ, and Wales AD. *Escherichia coli* O157:H7 colonization in small domestic ruminants. *FEMS Microbiol Rev* 2009;33:394–410.
23. Rice DH, Hancock DD, and Besser TE. Faecal culture of wild animals for *Escherichia coli* O157:H7. *Vet Rec* 2003;152:82–83.
24. Renter DG, Sargeant JM, Oberst RD, and Samadpour M. Diversity, frequency, and persistence of *Escherichia coli* O157 strains from range cattle environments. *Appl Environ Microbiol* 2003;69:542–547.
25. Orden JA, Cortes C, Horcajo P, De la Fuente R, Blanco JE, Mora A, Lopez C, Blanco J, Contreras A, Sanchez A, Corrales JC, and Dominguez-Bernal G. A longitudinal study of verotoxin-producing *Escherichia coli* in two dairy goat herds. *Vet Microbiol* 2008;132:428–434.
26. Battisti A, Lovari S, Franco A, Di Egidio A, Tozzoli R, Caprioli A, and Morabito S. Prevalence of *Escherichia coli* O157 in lambs at slaughter in Rome, central Italy. *Epidemiol Infect* 2006;134:415–419.
27. Ferens WA, Hovde CJ. (2011) *Escherichia coli* O157:H7: Animal Reservoir and Sources of Human Infection. *Foodborne Pathogens and Disease*. 2011;8(4):465-487. doi:10.1089/fpd.2010.0673.

28. Williams AP, McGregor KA, Killham K, Jones DL. Persistence and metabolic activity of *Escherichia coli* O157:H7 in farm animal faeces. *FEMS Microbiol Lett.* 2008;287(2):168-73.
29. Sugiyama A, Iwade Y, Akachi S, Nakano Y, Matsuno Y, Yano T, Yamauchi A, Nakayama O, Sakai H, Yamamoto K, Nagasaka Y, Nakano T, Ihara T, Kamiya H: An Outbreak of Shigatoxin-Producing
30. *Escherichia coli* O157:H7 in a Nursery School in Mie Prefecture. *Japanese Journal of Infectious Diseases* 2005, 58:398-400.
31. Public Health Laboratory Service: Outbreak of Vero cytotoxin-producing *Escherichia coli* O157 infection in a children's nursery in Suffolk. *CDR Weekly* 2000, 11:3.
32. Locking ME, Pollock KGJ, Allison LJ, Rae L, Hanson MF, Cowden JM. (2011) *Escherichia coli* O157 Infection and Secondary Spread, Scotland, 1999–2008. *Emerging Infectious Diseases.* 2011;17(3):524-527. doi:10.3201/eid1703.100167.
33. Snedeker KG, Shaw DJ, Locking ME, Prescott RJ. (2009) Primary and secondary cases in *Escherichia coli* O157 outbreaks: a statistical analysis. *BMC Infectious Diseases.* 2009;9:144. doi:10.1186/1471-2334-9-144.
34. Bell BP, Goldoft M, Griffin PM, Davis MA, Gordon DC, Tarr PI et al. A multistate outbreak of *Escherichia coli* O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. *JAMA* 1994; 272(17):1349-1353.
35. King LA, Mailles A, Mariani-Kurkdjian P, Vernozy-Rozand C, Montet MP, Grimont F et al. Community-wide outbreak of *Escherichia coli* O157:H7 associated with consumption of frozen beef burgers. *Epidemiol Infect* 2009; 137(6):889-896.
36. French multi-agency outbreak investigation team. 2005. Outbreak of *E. coli* O157:H7 infections associated with a brand of beefburgers in France. *Euro Surveill* 10(11):E051103.1.
37. Cowden JM, Ahmed S, Donaghy M, Riley A. Epidemiological investigation of the central Scotland outbreak of *Escherichia coli* O157 infection, November to December 1996. *Epidemiol Infect* 2001; 126(3):335-341.
38. McCartney G, Cowden J, Murray S, Ahmed S. The use of a new virtual cohort study design to investigate an outbreak of *E. coli* O157 linked to a supermarket delicatessen. *Epidemiol Infect* 2010; 138(10):1439-1442.
39. Rangel, JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL. "Epidemiology of *Escherichia coli* O157:H7 Outbreaks, United States, 1982–2002" (2005). *Public Health Resources.* Paper 73. *Emerging Infectious Diseases* 2005; 11(4): 603-609. Available from: <http://digitalcommons.unl.edu/publichealthresources/73>.
40. Health Protection Scotland (HPS) National Outbreak of *Escherichia coli* O157 Phage Type 32 in Scotland. September - October 2015 Report of the Incident Management Team. (April 2016). Available from: <http://www.hps.scot.nhs.uk/resourcedocument.aspx?id=2987>.
41. Trotz-Williams LA, Mercer NJ, Walters JM, Maki AM, Johnson RP. Pork implicated in a Shiga-toxin-producing *Escherichia coli* O157:H7 outbreak in Ontario, Canada. *Can J Public Health* 2012; 103(5): e322-6. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/23617981>.

42. Heuvelink AE, Zwartkruis-Nahuis JTM, van den Biggelaar FLAM, van Leeuwen WJ, and de Boer E. 1999. Isolation and characterization of verocytotoxin-producing *Escherichia coli* O157 from slaughter pigs and poultry. *Int J Food Microbiol* 52:67–75.
43. Espie E, Grimont F, Vailant V, Monlet MP, Carle I, Bavai C, de Valk H, Vernozy-Rozand C. (2006) O148 Shiga toxin-producing *Escherichia coli* outbreak: microbiological investigation as a useful complement to epidemiological investigation. *Clinical Microbiology and Infection* 2006; 12(10): 992-998. <https://doi.org/10.1111/j.1469-0691.2006.01468.x> Available from: <http://www.sciencedirect.com/science/article/pii/S1198743X14620292?via%3Dihub>.
44. Cowden, J. M., et al. “Epidemiological investigation of the central Scotland outbreak of *Escherichia coli* O157 infection, November to December 1996.” *Epidemiol.Infect.* 2001; 126(3): 335-41.
45. Health Protection Scotland (HPS) (2017) Incident Management Team Report. Outbreak of *E. coli* O157 PT21/28. Summer 2016. Available from: <http://www.hps.scot.nhs.uk/resourcedocument.aspx?id=5844>.
46. Gaulin C, Levac E, Ramsay D, Dion R, Ismail J, Gingras S et al. *Escherichia coli* O157:H7 outbreak linked to raw milk cheese in Quebec, Canada: use of exact probability calculation and casecase study approaches to foodborne outbreak investigation. *Journal of Food Protection* 2012; 75(5):812-818.
47. Upton P, Coia JE. Outbreak of *Escherichia coli* O157 infection associated with pasteurised milk supply. *Lancet* 1994; 344(8928):1015.
48. Goh S, Newman C, Knowles M, Bolton FJ, Hollyoak V, Richards S et al. *E. coli* O157 phage type 21/28 outbreak in North Cumbria associated with pasteurized milk. *Epidemiol Infect* 2002; 129(3):451-457.
49. Ackers ML, Mahon BE, Leahy E, Goode B, Damrow T, Hayes PS, et al. An outbreak of *Escherichia coli* O157:H7 infections associated with leaf lettuce consumption. *J Infect Dis.* 1998;177:1588–93.
50. Hilborn ED, Mermin JH, Mshar PA, Hadler JL, Voetsch A, Wojtkunski C, et al. A multistate outbreak of *Escherichia coli* O157:H7 infections associated with consumption of mesclun lettuce. *Arch Intern Med.* 1999;159:1758–64.
51. Li Y, Brackett RE, Chen J, Beuchat LR. 2001. Survival and growth of *Escherichia coli* O157:H7 inoculated onto cut lettuce before or after heating in chlorinated water, followed by storage at 5 °C or 15 °C. *J Food Prot* 64(3):305-9.
52. Harris LJ, Farber JN, Beuchat LR, Parish ME, Suslow TV, Garrett EH, Busta FF (2003) Outbreaks Associated with Fresh Produce: Incidence, Growth, and Survival of Pathogens in Fresh and FreshCut Produce in Comprehensive Reviews in Food Science and Food Safety (Chapter 3). Vol 2 (Supplement): 78-141.
53. European Food Safety Authority (EFSA) (2011) Shiga toxin-producing *E. coli* (STEC) O104:H4 2011 outbreaks in Europe: Taking stock. Scientific Report of EFSA. *EFSA Journal* 2011; 9(10): 2390. Available from: <https://www.efsa.europa.eu/en/efsajournal/pub/2390>.
54. Jenkins C, Dallman TJ, Launderers N, Willis C, Byrne L, Jorgenson F et al. Public Health investigation of two outbreaks of shiga toxin-producing *Escherichia coli* O157 associated with consumption of watercress. *Applied and Environmental Microbiology* 2015; 81 (12):3946-3952.

55. Launder N, Locking M, Hanson M, Willshaw G, Charlett A, Salmon R, . . . Adak G. (2016). A large Great Britain-wide outbreak of STEC O157 phage type 8 linked to handling of raw leeks and potatoes. *Epidemiology and Infection*, 144(1), 171-181. doi:10.1017/S0950268815001016. Available from: <https://www.cambridge.org/core/journals/epidemiology-and-infection/article/large-great-britainwide-outbreak-of-stec-o157-phage-type-8-linked-to-handling-of-raw-leeks-and-potatoes/B4CF8C1FB4E765B413CD50785B9B6E55#>.
56. Beatty M, Adcock PM, Smith S, Quinlan K, Kamimoto L, Rowe S, et al(2006). Epidemic Diarrhea due to Enterotoxigenic *Escherichia coli*. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 42. 329-34. 10.1086/499246.
57. Laidler MR, et al. *Escherichia coli* O157:H7 infections associated with consumption of locally grown strawberries contaminated by deer. *Clinical Infectious Diseases* 2013; 57: 1129–1134.
58. Neil KP, Biggerstaff G, MacDonald JK, Trees E, Medus C, Musser KA, Stroika SG, Zink D, Sotir MJ (2009) A Novel Vehicle for Transmission of *Escherichia coli* O157:H7 to Humans: Multistate Outbreak of *E. coli* O157:H7 Infections Associated With Consumption of Ready-to-Bake Commercial Prepackaged Cookie Dough—United States, 2009, *Clinical Infectious Diseases*, Volume 54, Issue 4, 15 February 2012, Pages 511–518, <https://doi.org/10.1093/cid/cir831>. Available from: <https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cir831>.
59. Duffy, G. (2003). Verocytotoxic *Escherichia coli* in animal feces, manures and slurries. *J Appl. Microbiol.* 94, 94S–103S. Available from: <http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2672.94.s1.11.x/pdf>.
60. Licence K, Oates KR, Synge BA, Reid TM. An outbreak of *E. coli* O157 infection with evidence of spread from animals to man through contamination of a private water supply. *Epidemiol Infect* 2001; 126(1):135-138.
61. Rajpura A, Lamden K, Forster S, Clarke S, Cheesbrough J, Gornall S, and Waterworth S. 2003. Large outbreak of infection with *Escherichia coli* O157 PT21/28 in Ecclestone, Lancashire, due to cross contamination at a butcher's counter. *Commun Disease Public Health* 6:279–284.
62. Jackson LA, Keene WE, McAnulty JM, Alexander ER, Diermayer M, Davis MA, Hedberg K, Boase J, Barrett TJ, Samadpour M, and Fleming DW. 2000. Where's the beef? The role of cross-contamination in 4 chain restaurant-associated outbreaks of *Escherichia coli* O157:H7 in the Pacific northwest. *Arch Intern Med* 160:2380–2385.
63. Doyle ME, Archer J, Kaspar CW, Weiss R. Human illness caused by *E. coli* O157:H7 from food and non-food sources. *FRI Briefings (Food Research Institute)* Aug-Oct 2006. Available from: https://fri.wisc.edu/files/Briefs_File/FRIBrief_EcoliO157H7humanillness.pdf.
64. Beatty M, Adcock PM, Smith S, Quinlan K, Kamimoto L, Rowe S, et al(2006). Epidemic Diarrhea due to Enterotoxigenic *Escherichia coli*. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 42. 329-34. 10.1086/499246.
65. Zhang XS, Chase-Topping ME, McKendrick IJ, Savill NJ, Woolhouse ME. Spread of *E. coli* O157 infection among Scottish cattle farms: stochastic models and model selection. *Epidemics* 2010; 2(1):11-20.

66. Chase-Topping ME, McKendrick IJ, Pearce MC, MacDonald P, Matthews L, Halliday J et al. Risk factors for the presence of high-level shedders of *Escherichia coli* O157 on Scottish farms. *J Clin Microbiol* 2007; 45(5):1594-1603.
67. Ihekweazu C, Carroll K, Adak B, Smith G, Pritchard GC, Gillespie IA, Large outbreak of verocytotoxin-producing *Escherichia coli* O157 infection in visitors to a petting farm in South East England, 2009. *Epidemiol Infect.* 2012;140:1400–13.
68. Heuvelink AE, Van Heerwaarden C, Zwartkruis-Nahuis JTM, Van Oosterom R, Edink K, Van Duynhoven YTHP, and De Boer E. 2002. *Escherichia coli* O157 infection associated with a petting zoo. *Epidemiol Infect* 129:295– 302.
69. CDC. MMWR. Outbreaks of *Escherichia coli* O157:H7 associated with petting zoos-- North Carolina, Florida, and Arizona, 2004 and 2005. *MMWR. Morbidity And Mortality Weekly Report* [serial on the Internet]. (2005, Dec 23); 54(50): 1277-1280.
70. Cho S, Bender JB, Diez-Gonzalez F, Fossler CP, Hedberg CW, Kaneene JB, Ruegg PL, Warnick LD, and Wells SJ. 2006. Prevalence and characterization of *Escherichia coli* O157 isolates from Minnesota dairy farms and county fairs. *J Food Prot* 69:252–259.
71. Crampin M, et al. Outbreak of *Escherichia coli* O157 infection associated with a music festival. *Eur.J Clin Microbiol Infect Dis* 1999; 18(4): 286-88.
72. Friedman MS, Roels T, Koehler JE, Feldman L, Bibb WF, and Blake P. 1999. *Escherichia coli* O157:H7 outbreak associated with an improperly chlorinated swimming pool. *Clin Infect Dis* 29:298–303.
73. Harrison S and Kinra S. 2004. Outbreak of *Escherichia coli* O157 associated with a busy bathing beach. *Commun Dis Public Health* 7:47–50.
74. Licence, K., et al. An outbreak of *E. coli* O157 infection with evidence of spread from animals to man through contamination of a private water supply. *Epidemiol.Infect.* (2001); 126(1): 135-38.
75. Browning L, Allison L, Couper S, Hanson M, Hawkins G, Smith-Palmer A (Health Protection Scotland). STEC in Scotland 2016: enhanced surveillance and reference laboratory data. *HPS Weekly Report* 2017; 51(2017/32). Available from: <http://www.hps.scot.nhs.uk/documents/ewr/pdf2017/1732.pdf>.
76. Money, P., Kelly, A. F., Gould, S. W. J., Denholm-Price, J., Threlfall, E. J. and Fielder, M. D. (2010), Cattle, weather and water: mapping *Escherichia coli* O157:H7 infections in humans in England and Scotland. *Environmental Microbiology*, 12: 2633–2644. doi:10.1111/j.1462-2920.2010.02293.x.
77. Locking ME, Pollock KGJ, Allison LJ, Rae L, Hanson MF, Cowden JM. (2011) *Escherichia coli* O157 Infection and Secondary Spread, Scotland, 1999–2008. *Emerging Infectious Diseases*. 2011;17(3):524-527. doi:10.3201/eid1703.100167.
78. Sheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated haemolytic uraemic syndrome (HUS) *Pediatr Nephrol* 2008; 23: 1749-1760. Available from: <https://link.springer.com/article/10.1007%2Fs00467-008-0935-6>.
79. Public Health etc. (Scotland) Act 2008 (asp 5). Available from: <http://www.legislation.gov.uk/asp/2008/5/contents>.

80. Schmidt, H., Scheef, J., Huppertz, H. I., Frosch, M., & Karch, H. (1999). *Escherichia coli* O157:H7 and O157:H– Strains That Do Not Produce Shiga Toxin: Phenotypic and Genetic Characterization of Isolates Associated with Diarrhea and Hemolytic-Uremic Syndrome. *Journal of Clinical Microbiology*, 37(11), 3491–3496. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC85676/>.
81. Rump LV, Gonzalez-Escalona N, Ju W, Wang F, Cao G, Meng S, Meng J (2015) Genomic Diversity and Virulence Profiles of Historical *Escherichia coli* O157 Strains Isolated from Clinical and Environmental Sources. *Appl. Environ. Microbiol.* January 2015 81:2 9 569-577. Available from: <http://aem.asm.org/content/81/2/569.full>.
82. Ferdous M, Zhoua K, Mellmannb A, Morabitoc S, Croughsd PD, de Boere RF, Kooistra-Smida AMD, Rossena JAW, Friedricha JA. (2015) Is Shiga Toxin-Negative *Escherichia coli* O157:H7 Enteropathogenic or Enterohemorrhagic *Escherichia coli*? Comprehensive Molecular Analysis Using Whole-Genome Sequencing. *J. Clin. Microbiol.* 2015 53:11 3530-3538. doi:10.1128/JCM.01899-15. Available from: <http://jcm.asm.org/content/53/11/3530.short>.
83. Kossov A, W Zhang, Bielaszewska M, Rhode S, Hansen K, Fruth A, Rüter C, Karch H, Mellmann A. (2016) Molecular Characterization of Human Atypical Sorbitol-Fermenting Enteropathogenic *Escherichia coli* O157 Reveals High Diversity. *J. Clin. Microbiol.* 2016 54:5 1357-1363; doi:10.1128/JCM.02897-15. Available from: <http://jcm.asm.org/content/54/5/1357.short>.
84. EFSA (2013) Scientific Opinion on VTEC-seropathotype and scientific criteria regarding pathogenicity assessment. *EFSA Journal* 2013;11(4):3138. Available from: <https://www.efsa.europa.eu/en/efsajournal/pub/3138>.
85. BFR. EHEC Outbreak 2011 Investigation of the Outbreak Along the Food Chain. Bundesinstitut für Risikobewertung. 2012. Available from: <http://bfr.bund.de/cm/350/ehec-outbreak-2011-investigation-of-the-outbreak-along-the-food-chain.pdf>.
86. Bielaszewska M, Friedrich AW, Aldick T, Schürk-Bulgrin R, Karch H; Shiga Toxin Activatable by Intestinal Mucus in *Escherichia coli* Isolated from Humans: Predictor for a Severe Clinical Outcome. *Clin Infect Dis* 2006; 43 (9): 1160-1167. doi: 10.1086/508195 <https://academic.oup.com/cid/article-lookup/doi/10.1086/508195>.
87. Melton-Celsa, A. R., O'Brien, A. D., & Feng, P. C. H. (2015). Virulence Potential of Activatable Shiga Toxin 2d-Producing *Escherichia coli* Isolates from Fresh Produce. *Journal of Food Protection*, 78(11), 2085–2088. <http://doi.org/10.4315/0362-028X.JFP-15-180>. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835030/>.
88. Jelacic JK, Damrow T, Chen GS, Jelacic S, Bielaszewska M, Ciol M, Carvalho HM, Melton-Celsa AR, O'Brien AD, Tarr PI (2003). Shiga Toxin-Producing *Escherichia coli* in Montana: Bacterial Genotypes and Clinical Profiles. *J Infect Dis* 2003; 188 (5): 719-729. doi: 10.1086/376999. <https://academic.oup.com/jid/article/188/5/719/850918/Shiga-Toxin-Producing-Escherichia-coli-in-Montana>.
89. Feng, P. C. H., & Reddy, S. (2013). Prevalences of Shiga Toxin Subtypes and Selected Other Virulence Factors among Shiga-Toxigenic *Escherichia coli* Strains Isolated from Fresh Produce. *Applied and Environmental Microbiology*, 79(22), 6917–6923. <http://doi.org/10.1128/AEM.02455-13> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811557/>.

90. Fuller, C. A., Pellino, C. A., Flagler, M. J., Strasser, J. E., & Weiss, A. A. (2011). Shiga Toxin Subtypes Display Dramatic Differences in Potency . *Infection and Immunity*, 79(3), 1329–1337. <http://doi.org/10.1128/IAI.01182-10> Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3067513/>.
91. LACHER D, GANGIREDLA J, PATEL I, ELKINS CA, and FENG PCH (2016) Use of the *Escherichia coli* Identification Microarray for Characterizing the Health Risks of Shiga Toxin–Producing *Escherichia coli* Isolated from Foods. *Journal of Food Protection*: October 2016, Vol. 79, No. 10, pp. 1656-1662.
92. Monaghan A, Byrne B, Fanning S, Sweeney T, McDowell D, Bolton DH. Serotypes and Virulence Profiles of Non-O157 Shiga Toxin-Producing *Escherichia coli* Isolates from Bovine Farms *Appl. Environ. Microbiol.* December 2011 77:24 8662-8668; doi:10.1128/AEM.06190-11 Available from: <http://aem.asm.org/content/77/24/8662.short>.
93. European Food Safety Authority (EFSA), European Centre for Disease Prevention and Control (ECDC). The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2014. *EFSA Journal* 2015 (amended 2016);13(12):4329.
94. Food Standards Agency (FSA) *E. coli* O157 Control of Cross-contamination Guidance for food business operators and local authorities. 2014. Available from: <https://www.food.gov.uk/sites/default/files/ecoli-cross-contamination-guidance.pdf>.
95. Health Protection Scotland (2016) Infection Prevention and Control in Childcare Settings (Day Care and Childminding Settings). Scottish Health Protection Network, Health Protection Scotland, NHS National Scotland Services. Available from: <http://www.hps.scot.nhs.uk/haic/ic/resourcedetail.aspx?id=352> . See also further information on National Infection Prevention and Control Manual available from: <http://www.nipcm.hps.scot.nhs.uk/>.
96. Padola N, Etcheverría A. Shiga toxin-producing *Escherichia coli* in human, cattle, and foods. Strategies for detection and control. *Frontiers in Cellular and Infection Microbiology* July 2014; 4(Article 89): 1-2. doi: 10.3389/fcimb.2014.00089.
97. Matussek A, Einemo IM, Jogenfors A, Löfdahl S, Löfgren. Shiga Toxin-Producing *Escherichia coli* in Diarrheal Stool of Swedish Children: Evaluation of Polymerase Chain Reaction Screening and Duration of Shiga Toxin Shedding. *Journal of the Pediatric Infectious Diseases Society* 2015; 5 (2): 147–151. <https://doi.org/10.1093/jpids/piv003>. Available from: <https://academic.oup.com/jpids/article/5/2/147/2580163/Shiga-Toxin-Producing-Escherichia-coli-in>.
98. Scottish CPHM (Health Protection) Group; Good Practice Statement: Management of Cases and Contacts of Infectious Intestinal Disease. March 2014.
99. Gilbert M, Monk C, Wang HL, Diplock K, Landry L. Screening policies for day-care attendees: Lessons learned from an outbreak of *E. coli* O157:H7 in a daycare in Waterloo, Ontario. *Canadian Journal of Public Health* 2008; 99(4): 281-5. Available from <http://search.proquest.com/docview/232006449?accountid=145948>.
100. Swerdlow DL, Griffin P. Duration of faecal shedding of *Escherichia coli* O157:H7 among children in day-care centres. *The Lancet* 1997; 349:745-6.

101. Canadian Agency for Drugs and Technologies in Health. Screening of Shiga-toxigenic *Escherichia coli* in Clinical Fecal Samples: A Review of Diagnostic Accuracy, Clinical Utility, Cost-Effectiveness and Guidelines. Rapid Response Report: Summary with Critical Appraisal. 2015. Available from: <https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0078901/>.
102. Public Health England (PHE). Guidance on Infection Control in Schools and other Childcare Settings 2016. Available from: <https://www.gov.uk/government/publications/infection-control-in-schools-poster>.
103. Public Health etc. (Scotland) Act 2008 (asp 5); Part 4. Public Health Functions of Health Boards. Sections 37, 38; pp. 25-27. Available from: <http://www.legislation.gov.uk/asp/2008/5/contents>.
104. Public Health etc. (Scotland) Act 2008 (asp 5). Available from: <http://www.legislation.gov.uk/asp/2008/5/contents>.
105. Dabke G, Le Menach A, Black A, Gamblin J, Palmer M, Boxall N, Booth L. Duration of shedding of verocytotoxin-producing *Escherichia coli* in children and risk of transmission in childcare facilities in England. *Epidemiology and Infection* 2014; 142(2): 327-334.
106. Dabke G, Le Menach A, Black A, Gamblin J, Palmer M, Boxall N, Booth L. Duration of shedding of verocytotoxin-producing *Escherichia coli* in children and risk of transmission in childcare facilities in England. *Epidemiology and Infection* 2014; 142(2): 327-334.
107. Swerdlow D. Duration of faecal shedding of *Escherichia coli* O157:H7 among children in day-care centres. *The Lancet* 1997, Volume 349, Issue 9054, 745 – 746. Available from: [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(05\)60196-1/references](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)60196-1/references).
108. Vonberg RP. Duration of faecal shedding of Shiga-toxin producing *Escherichia coli* O104:H4 in patients infected during the 2011 outbreak in Germany: A multicentre study. *Clin Infect Dis*. 2013 Apr; 56(8): 1132-40.
109. Caprioli A, Morabito A, Brugere H, Oswald E. Enterohaemorrhagic *Escherichia coli*: emerging issues on virulence and modes of transmission. *Veterinary Research, BioMed Central*, 2005, 36 (3), pp.289-311.
110. Health Protection Agency (2011). Report on the work of the Godstone Multi-Agency Implementation Committee. Available from Public Health England (PHE): <https://www.gov.uk/government/publications/escherichia-coli-e-coli-o157-report-and-recommendations-from-2009-godstone-incident>.
111. Scottish Government. Management of Public Health Incidents: Guidance on the Roles and Responsibilities of NHS Led Incident Management Teams. Scottish Health Protection Network. Scottish Guidance 12 (2017 edition). Health Protection Scotland, 2017. Available at: <http://www.hps.scot.nhs.uk/resourcedocument.aspx?id=6038>.
112. Karch H, Russmann H, Schmidt H, et al. Long-term shedding and clonal turnover of enterohemorrhagic *Escherichia coli* O157 in diarrhoeal diseases. *J Clin Microbiol* 1995; 33: 1602-5.

113. Shah S, Hoffman R, Shillam P, et al. Prolonged faecal shedding of *Escherichia coli* O157:H7 during an outbreak at a day care centre. *Clin Infect Dis* 1996; 23: 835-6.
114. Health Protection Scotland (2016) Infection Prevention and Control in Childcare Settings (Day Care and Childminding Settings). Scottish Health Protection Network, Health Protection Scotland, NHS National Scotland Services. Available from: <http://www.hps.scot.nhs.uk/haic/ic/resourcedetail.aspx?id=352> . See also further information on National Infection Prevention and Control Manual available from: <http://www.nipcm.hps.scot.nhs.uk/>.
115. MacDonald E, Dalane PK, Aavitsland P, Brandal LT, Wester LA, Vold L. Implications of screening and childcare exclusion policies for children with Shiga-toxin producing *Escherichia coli* infections: lessons learned from an outbreak in a daycare centre, Norway, 2012. *BMC Infectious Diseases* 2014; 14: 673.
116. Kanayama A, Yuichiro Y, Yuzo A, Takuri T, Takehito S, Kazuhiko K, Kunio K, Tomimasa S, Tamano M, Kazunori O. Enterohemorrhagic *Escherichia coli* outbreaks related to childcare facilities in Japan, 2010–2013. *BMC Infectious Diseases* 2015; 15: 539. DOI: 10.1186/s12879-015-1259-3.
117. NHS Grampian, Aberdeenshire Council. Outbreak of *E. coli* O157 infection at Rose Lodge Nursery, Aboyne May 2012 Report of the Incident Management Team. 2012. Available from: <http://www.nhsgrampian.org/files/Item10.4.1CGCReportIMTReport.pdf>.
118. Dabke G, Le Menach A, Black A, Gamblin J, Palmer M, Boxall N, Booth L. Duration of shedding of verocytotoxin-producing *Escherichia coli* in children and risk of transmission in childcare facilities in England. *Epidemiology and Infection* 2014; 142(2): 327-334.
119. Health Protection Agency (2011). Report on the work of the Godstone Multi-Agency Implementation Committee. Available from Public Health England (PHE): <https://www.gov.uk/government/publications/escherichia-coli-e-coli-o157-report-and-recommendations-from-2009-godstone-incident>.
120. Health and Safety Executive (HSE). Preventing or controlling ill health from animal contact at visitor attractions or open farms. Available from: <http://www.hse.gov.uk/agriculture/topics/visitor-attractions.htm>.
121. Access to Farms Partnership. Preventing or Controlling Ill Health from Animal Contact at Visitor Attractions. Industry Code of Practice. Version 2 (Updated March 2015) <http://www.visitmyfarm.org/component/k2/content/2-healthandsafety>. England, 2015.
122. Health and Safety Executive. AIS23 - Preventing or controlling ill health from animal contact at visitor attractions. See info online (publication withdrawn) from: <http://www.hse.gov.uk/pubns/ais23.htm> . New Code of Practice available from: <http://www.visitmyfarm.org/component/k2/content/2-healthandsafety>. Information can now be obtained from [Farming and Countryside Education](#).
123. Farming and Countryside Education (FACE). Available from: <https://www.face-online.org.uk/for-farmers/new-to-farm-visits>. See also Visit My Farm at: <http://www.visitmyfarm.org/>.
124. The Royal Environmental Health Institute of Scotland (REHIS). New Code of Practice on Animal Contact at Visitor Attractions. Available from: <http://www.rehis.com/story/2012/06/new-code-practice-animal-contact-visitor-attractions>.

125. Health and Safety Executive. Preventing or controlling ill health from animal contact at visitor attractions - Guidance on inspection and enforcement. 2016 (May). Available from: http://www.hse.gov.uk/foi/internalops/sims/ag_food/011102/index.htm.
126. Erdozain G, KuKanich K, Chapman B, Powell D. Best practices for planning events encouraging human-animal interactions. *Zoonoses And Public Health* [serial online]. 2015 (March); 62(2): 90-99. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/24751220>.
127. CDC. Outbreaks of *Escherichia coli* O157:H7 associated with petting zoos--North Carolina, Florida, and Arizona, 2004 and 2005. *MMWR. Morbidity And Mortality Weekly Report* [serial on the Internet]. 2005, (Dec 23); 54(50): 1277-1280.
128. Møller-Stray J, Eriksen HM, Bruheim T, Kapperud G, Lindstedt BA, Skeie Å, Sunde M, Urdahl AM, Øygard B, Vold L. Two outbreaks of diarrhoea in nurseries in Norway after farm visits, April to May 2009. *Euro Surveill.* 2012;17(47):pii=20321. Available from: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20321>.